CAPLIPOINT share price, P/E, ROE & financials

As of 6 Nov 2026, Caplin Point Laboratories trades at 27.3× trailing earnings, below the industry P/E of 28.7×, and the shares are 20% below their 52-week high. Sales and net profit grew 14% and 19% a year over 3 years; its ROCE of 22% is the highest among the 7 largest Drug Manufacturers (Specialty & Generic) peers. It carries very little debt, and its dividend yield is 0.3%. It is a small-cap company with a market cap of ₹18,110 Cr, ranked 25th of 154 Drug Manufacturers (Specialty & Generic) companies by market cap; the shares rose 21% over the past year.

As of 6 Nov 2026Prices are delayed about 15 minutes; fundamentals are from the quarter ended Jun 2026.How we calculate this

past year

Open: ₹2,409.00
Day high: ₹2,410.00
Day low: ₹2,360.20
Prev. close: ₹2,421.40
Volume: 23.8K

Health check

3 good · 3 fair

ReturnsIn line
+21.4% over a year, better than 3 of 7 peers.
Price tagIn line
P/E 27.3 vs industry 28.7.
GrowthStrong
Sales +14.3%, profit +19.4% a year over 3 years.
ProfitabilityStrong
ROCE 22.0% vs peer median 17.9%.
Balance sheetFair
Practically debt-free, Piotroski 5 of 9.
Red flagsNone found
No warning signs in the headline numbers.

Compared with 7 industry peers. Computed from reported figures. Educational, not a recommendation.

Drug Manufacturers - Specialty & Generic

153 listed peers. Screen the industry

Small cap

₹18,110 Cr, #25 of 154 in its industry by size.

Defensive

Beta 0.46 vs the NIFTY 50: moves less than the market.

Key metrics

Last 12 months to Jun 2026: sales ₹2,287 Cr · profit ₹665 Cr

Market cap: ₹18,110 Cr; Small cap
P/E: 27.3; Industry 28.7
Price to book: 5.16; Peers 4.99
Dividend yield: 0.34%
ROE: 19.9%; Peers 14.7%
ROCE: 22.0%; Peers 17.9%
Debt to equity: 0.00; Debt ₹4.61 Cr
EPS (TTM): ₹87.28; Face value ₹2
OPM (TTM): 34.7%; Net margin 29.1%
Sales growth: +19.6%; Latest quarter vs a year ago
Profit growth: +15.8%; Latest quarter vs a year ago
Price to sales: 7.92; EV/EBITDA 21.7

Strengths

Return on equity of 19.9%.
Return on capital employed of 22.0%.
Practically debt-free.
Quarterly sales up 19.6% on a year ago.
Net margin of 29.1%.

No obvious red flags in the headline numbers.

Derived automatically from reported figures. Not a recommendation.

About Caplin Point Laboratories

Caplin Point Laboratories Limited, together with its subsidiaries, engages in the development, production, marketing, and export of generic formulations and branded products in India. The company provides tablets, capsules, injections, ophthalmic, liquid orals, softgel, capsules, ointments, creams and gels, powder for injections, suppositories, ovules, pre-mix bag, inhalers, and sprays and IV infusion. It also provides dry and syrups, lyophilized vials,…

Headquarters: Chennai
Employees: 4,199
Sector: Healthcare
ISIN: INE475E01026
Website: caplinpoint.net

Price range

52 weeks

₹1,500.30₹2,990.00

Today

₹2,360.20₹2,410.00

Avg volume (3M): 1.8 L
1-year return: plus 21.4%
From 52-week high: minus 20.3%

Peers · Drug Manufacturers - Specialty & Generic

Compare with peers Screen the whole industry

Company
SUNPHARMASun Pharmaceutical Industries	1,860.00	plus 1.69%	4,46,276	40.7	4.99	17.9%	13.1%	28.2%	10.4%	10.6%	0.86%	plus 8.2%
DIVISLABDivi's Laboratories	10,320.50	plus 1.78%	2,73,977	93.6	16.35	19.0%	16.2%	34.9%	11.0%	12.1%	0.29%	plus 49.0%
TORNTPHARMTorrent Pharmaceuticals	4,750.00	plus 0.85%	1,80,675	80.2	9.83	9.1%	15.7%	33.7%	13.3%	20.2%	0.80%	plus 31.7%
LAURUSLABSLaurus Labs	2,340.00	minus 0.26%	1,26,433	94.4	20.86	19.5%	24.0%	30.4%	3.8%	4.0%	0.09%	plus 138.6%
ZYDUSLIFEZydus Lifesciences	1,197.90	plus 0.41%	1,19,491	28.6	4.29	19.0%	14.7%	26.2%	16.5%	37.0%	0.08%	plus 22.8%
DRREDDYDr. Reddy's Laboratories	1,373.00	plus 0.51%	1,14,462	40.9	2.96	14.2%	7.3%	15.9%	11.0%	−1.7%	0.58%	plus 13.8%
CIPLACipla	1,411.00	plus 0.49%	1,13,993	39.4	3.22	14.9%	8.3%	17.3%	7.2%	11.5%	0.92%	minus 6.6%
CAPLIPOINTCaplin Point Laboratories	2,382.50	minus 1.61%	18,110	27.3	5.16	22.0%	19.9%	34.7%	14.3%	19.4%	0.34%	plus 21.4%
Median of 7 peers	–	0.51%	1,26,433	40.9	4.99	17.9%	14.7%	28.2%	11.0%	11.5%	0.58%	22.8%

Quarterly results

Consolidated, ₹ crore

SalesSelect a row below to chart it

Mar 25	Jun 25	Dec 25	Mar 26	Jun 26
502	510	543	600	610
–	–	–	+19.4%	+19.6%
334	332	353	396	397
168	178	190	204	213
33.4%	34.8%	34.9%	34.0%	35.0%
29.6	23.2	33.7	28.4	33.5
0.2	0.2	0.2	0.4	0.2
17	16.3	19.3	18.8	21.6
−3.8	–	–	–	–
177	184	204	213	225
17.8%	18.3%	18.7%	19.0%	20.5%
143	153	164	170	177
–	–	–	+19.3%	+15.8%
18.69	20.03	21.51	22.31	23.21

Sep 25 not reported by the data source.

Profit & loss

Yearly, ₹ crore

Sales CAGR 3Y: +14.3%
Profit CAGR 3Y: +19.4%
EPS CAGR 3Y: +19.6%
ROE: 19.9%

Net profitSelect a row below to chart it

Mar 2023	Mar 2024	Mar 2025	Mar 2026
1,454	1,680	1,921	2,171
–	+15.5%	+14.4%	+13.0%
1,010	1,128	1,268	1,404
443	551	653	767
30.5%	32.8%	34.0%	35.3%
52.8	67.2	94.1	94.3
0.8	0.8	0.6	0.9
45	53.4	66	72.8
0.9	–	−3.8	14.8
451	564	677	803
16.5%	18.3%	20.0%	19.1%
376	457	536	641
–	+21.5%	+17.3%	+19.6%
49.18	59.90	70.25	84.11

Forecast

Your assumptions, not a prediction

Balance sheet

At each financial year end, ₹ crore

Total assetsSelect a row below to chart it

Mar 2023	Mar 2024	Mar 2025	Mar 2026
15.2	15.2	15.2	15.2
1,865	2,301	2,835	3,571
5.5	2	5	4.6
305	380	355	454
2,191	2,698	3,211	4,045
489	557	674	760
220	117	139	209
69.4	136	301	481
695	784	960	992
717	1,105	1,136	1,605
2,191	2,698	3,211	4,045

Cash flow

Yearly, ₹ crore

Cash from operationsSelect a row below to chart it

Mar 2023	Mar 2024	Mar 2025	Mar 2026
271	318	432	523
−218	−320	−335	−582
−28.2	−38.1	−38.3	−46.5
25.6	−39.7	59.3	−106
−193	−146	−192	−248
77.9	173	241	275
−30.3	−34.2	−38	−45.6

Shareholding pattern

Source: NSE filings

70.6%

promoters

Promoters70.57%
Public29.43%
As of 30 Sep 2026

Quarter	Promoters	Public	Promoter change
30 Sep 2026	70.57%	29.43%	0.00
30 Jun 2026	70.57%	29.43%	0.00
31 Mar 2026	70.57%	29.43%	0.00
31 Dec 2025	70.57%	29.43%	0.00
30 Sep 2025	70.57%	29.43%	–

Major shareholders

NSE filing

Filings & events

News

No recent news coverage found.

My notes

Private to you